Recent submissions

Comment · 5 years ago
Not only that, but many nonprofits must force their employees and even volunteers to use annoying time tracking software!
Comment · 5 years ago
I was floored to discover Reddit is violating Google’s Auth TOS! Check this out:

1. Log in using your Google account.

2. Log out of reddit.

3. Clear your Reddit cookies.

4. Visit Reddit again.

You’ll be automatically logged in..!! This is nuts, shady, and a violation of the Google TOS. You can’t keep users’ auth tokens, secretly, and then log them back in when you feel like it. A user clicking “log out” means you expire the auth token.

Comment · 6 years ago
In large dense American cities there are risks with even going outside on a walk. There are stories of people who didn’t leave their homes except on walks but caught COVID-19. There was a NYT columnist who got it and hadn’t done anything except go on walks in NYC. That seems statistically odd to me, because there can’t be that many NYT columnists.

Consider that to go outside, many in a large city must leave their flat, walk down a shared hallway, walk past other people’s front doors, use an elevator, etc.

There’s also a lot of people on the sidewalk, many without masks, who will walk right past you, often talking loudly on a cell phone. It’s often not possible to avoid walking close to these people due to small sidewalks and busy city streets.

Obviously the risk is lower than other activities but it’s not the same as going outside in the suburbs or driving somewhere. In my city, on a 40 minute walk I pass several hundred people. In my building here, none of the other residents wear masks and to enter and exit I must walk past their front doors.

So I would say it’s quite safe. But it’s not quite as safe in big, dense American city as in the suburbs.

Comment · 6 years ago
I added “beside the point” because I believe so, yeah.
Comment · 6 years ago
None of the items were life or death essentials. These were things like protein cookies, pet-themed gifts, exercise equipment, etc. I wouldn’t have bought them if I never saw the ads.

But wanting and needing are different things. I wouldn’t consider it manipulation to show me something I might be interested in that I wouldn’t have known about otherwise. For instance, I just discovered (via ads) the galaxy night light trend and I’m now thinking it might be fun to get one.

Comment · 6 years ago
I might be one of the few, but I like the ads I see on Instagram and have purchased lots of things via IG ads. I can’t think of any other app/site where the ads have sucked me in.

I realize this is besides the point, but I thought it was worth sharing in terms of how they might be doing personalization. For me, it’s so good that it actually works.

Comment · 6 years ago
The problem I see with this trial is that it’s open-label, small n, and has subjective endpoints (ICU admission as the primary outcome). The study is underpowered to detect mortality. Given the open-label nature of the trial, the subjective outcome with the small n makes this result less strong.

Why is this the case? Well, for this trial the physicians treating patients knew who got the Vitamin D and who didn’t, and thus they may have been more likely to admit those who didn’t to the ICU (subjective). Something like mortality is not as subjective, but there are too few study participants to detect a mortality signal in this trial.

If I had been conducting this small open label trial I would have picked some less subjective outcomes, like maybe P/F Ratio.

Comment · 6 years ago
I guess what I think could be possible is:

ARBs upregulate ACE2 but within normal physiological limit (see other comment). My understanding is it is the Ang II activation of AT2R that drives the increase in ACE2 expression. In this case, we would expect children and women (estrogen upregulates AT2R, downregulates AT1R) to have higher ACE2 in the presence of increased Ang II. I think children may have more AT2R. https://twitter.com/__philipn__/status/1233569567512772609?s... but this may be beside the point.

Other coronaviruses that use more common receptors are not as lethal. Even if the virus has a higher probability of cell entry, does that make it more lethal?

Check out this paper:

https://twitter.com/__philipn__/status/1229568317167243264?s...

Proportion of reduction of ACE2 correlates with disease severity.

Check out figure 1

“Differences in clinical outcomes did not correlate with differences in viral replication efficiencies.”

Compare C and D. Viral replication basically the same between young and old mice. But old had severe disease.

So I’m not sure it’s as simple as increased replication (a proxy for cell entry?) that drives severity.

Edit: just re read your final sentence. Great point. But in the case of ARB usage, while ACE2 may be upregulated and the cell may have another ACE2 cleaved by the virus, if AT1R blockade was occurring then maybe the lung damage would not happen.

Is the cell itself worse off with more than one copy of the virus inside of it? Or would the damage be the increased loss of ACE2?

If damage from increased loss, then I can see the ARB approach helping.

If more than one copy of virus in cell is really bad, then sounds like this could be more complicated. But I do wonder about other viruses which have lots of receptors available, and why this one is so serious in some, but not most, people.

Comment · 6 years ago
Just a little clarification. These renin-angiotensin terms are totally confusing (due to how similar they all are!) and from my correspondence with physicians, many of them even get them mixed up!

Virus binds to and downregulates ACE2. ACE2 converts Ang II to Ang 1-7. Ang II binds to AT1R and AT2R receptors:

https://twitter.com/__philipn__/status/1229607854232850432?s...

Pic for clarity.

When there’s less ACE2, and in general due to immune response, there will be more Ang II to bind to AT1R. This AT1R binding may create the lung injury seen with the virus.

The idea is that by blocking AT1R with an ARB type drug you don’t stop the virus from entering a cell, but you instead stop the body’s pathological response to the virus. After all, most viruses don’t kill us, and our immune system - if it doesn’t over react - will usually kill a thing if it has enough time and the virus isn’t “special” like HIV or herpes (that’s my general, non expert understanding!)

While it seems smart to try and inhibit ACE2 directly, there are a couple problems with this I see:

1. It may be pathological. More Ang II to bind to AT1R, you might end up way worse off. ACE2 is the “good” ACE, and all the evidence we have seems to suggest that a reduction in the ACE2:ACE ratio will make tissue fibrosis, death, etc worse. This happens in the heart and lungs in mouse models.

2. Small molecule ACE2 inhibitors bind to the C shaped area of the ACE2 enzyme, while the virus attaches to the back. So they likely may not inhibit cell entry:

https://twitter.com/robertlkruse/status/1230577662751641601?...

The best silver bullet bet here is ACE2-fc, which isn’t a small molecule.

This is a soluble form of the ACE2 protein along with an fc. this gives it a longer half life in the body.

This would likely:

1. Stop virus cell entry by neutralizing the virus- virus binds to ACE2-fc instead of the cell ACE2.

2. Stop potential lung damage from AT1R activation.

Both 1 and 2 have been shown in some models.

It is now being tested in vitro. Next animals.

Chinese are testing non-fc form, ACE2 directly, but requires IV drip. Testing now directly in humans! 7 day trial.

See twitter for more on this:

https://twitter.com/__philipn__

If you’re a funder, VC and you’re reading this: The scientist at John Hopkins who’s developing ACE2-fc is looking for funding. He’s working with Chinese biotech firms now to do the testing. Please comment here and I will connect you.

Comment · 6 years ago
Comment · 6 years ago
I wrote a long comment and it got deleted, argh!

Best guess? ACE2 loss is probably bad, having more ACE2 probably doesn’t drive disease severity:

https://twitter.com/__philipn__/status/1229568317167243264?s...

Relative ace2 reduction correlates w disease severity; viral load growth the same between groups - check out study!

Chinese paper discusses this as well:

https://pubmed.ncbi.nlm.nih.gov/32061198-inhibitors-of-ras-m...

They reason that 1) ARB doesn’t increase ACE2 past normal human baseline anyway, just to normal status 2) Younger have higher ACE2, older women more than older men; both groups more protected so disease severity unlikely from higher ACE2.

ACE2-fc being developed- will both stop AT1R activation and neutralize virus:

https://twitter.com/robertlkruse/status/1233986542097567744?...

He is looking for funding if any funders are reading this. Comment here and I can connect.

Live from the official Hacker News API

A modern reader for Hacker News · SvelteKit + Skeleton